Skip to main content
By kristalamb
Posted date: August 07, 2019
[siteorigin_widget class=”SiteOrigin_Widget_Image_Widget”][/siteorigin_widget]

Researchers in Toronto (Bruce Perkins MD) and Montreal (Ahmad Haidar PhD) and their teams have started the “Closed Loop ASSessment 17 (CLASS17)” study investigating how a pill used for the management of type 2 diabetes can help a hybrid closed loop insulin pump system work better to achieve time-in-target blood sugar levels for those with type 1 diabetes. The pill is a type of Sodium-Glucose Linked Transporter (SGLT) inhibitor that lowers blood sugar by increasing the urinary excretion of sugar. The hybrid closed loop system uses a Dexcom sensor, a Tandem insulin pump, and the McGill Artificial Pancreas algorithm run on an Android phone.

For more information about the study, see or e-mail


Tidepool working with diabetes device manufacturers to empower the diabetes community with their health data

Scientific Ambassadors’ Report From the Joint Annual Meeting of SQLNM, CMDO Network, and Colossus Congress is now Available!